Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Equity Ratio (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Equity Ratio data on record, last reported at 0.92 in Q3 2025.

  • For Q3 2025, Equity Ratio fell 0.6% year-over-year to 0.92; the TTM value through Sep 2025 reached 0.92, down 0.6%, while the annual FY2024 figure was 0.92, 9.51% up from the prior year.
  • Equity Ratio reached 0.92 in Q3 2025 per CYCN's latest filing, roughly flat from 0.91 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q4 2024 and bottomed at 0.34 in Q1 2023.
  • Average Equity Ratio over 5 years is 0.77, with a median of 0.84 recorded in 2023.
  • Peak YoY movement for Equity Ratio: tumbled 56.96% in 2023, then soared 154.86% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.81 in 2021, then dropped by 28.9% to 0.58 in 2022, then skyrocketed by 45.99% to 0.84 in 2023, then grew by 9.51% to 0.92 in 2024, then dropped by 0.92% to 0.92 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.92 in Q3 2025, 0.91 in Q2 2025, and 0.89 in Q1 2025.